Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study

Gribetz, Carin; Ling, Mark; Lebwohl, Mark; Pariser, David M.; Draelos, Zoe Diana; Gottlieb, Alice B.; Zaias, Nardo; Chen, Diana M.; Parneix-Spake, Anne; Hultsch, T.; Menter, Alan

doi:10.1016/j.jaad.2004.06.010

Cited by 111 publications

(99 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topikal antralin türevle-ri %10.7, pimekrolimus ise %3.5 hastada tercih edilmiştir. Topikal kalsinörin inhibitörleri de son yıllarda psoriazis tedavisinde yan etkilerinin topikal steroidlere oranla daha az olması nedeni ile özellikle topikal steroidleri kullanamadığımız intertrijinöz böl-geler, yüz, göz kapağı gibi alanlarda kullanılmaktadır [19]. Bizim çalışmamızda da pimekrolimus invers psoriasisli hastalarda istatistiksel olarak daha fazla tercih edilmiştir.…”

Section: Discussionunclassified

Clinical and Demographic Characteristics of 626 Patients with Moderate and Severe Psoriasis

Rifaioğlu¹,

Özarmağan²

2014

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Çalışmamızda İstanbul Üniversitesi İstanbul Tıp Fakültesi Dermatoloji Anabilim Dalı psoriazis polikliniğinde takip edilen orta ve şiddetli psoriazis hastalarının demografik özelliklerini, klinik tiplerini ve kullanılan tedavileri incelemeyi amaçladık. Gereç ve Yöntem: Psoriazis polikliniğinde 2002-2008 yıl-ları arasında izlenen 1831 hasta tarandı, ve içlerinden orta ve şiddetli 626 (%34) olgu retrospektif olarak değerlendirildi. Bulgular: Çalışmamıza katı-lan olguların 305'i (%48.7) kadın, 321'i (%51.3) erkek olarak bulundu. Hastalık başlangıç yaşı 28.1 yıl ve en sık görülen klinik tip plak psoriazis olarak saptandı. Tırnak tutulumu saptanan hastalarda en sık pitting gözlendi. Artriti olan hastalarda tırnak tutulumu görülme sıklığı anlamlı şekilde yüksek bulundu. Ailede psoriazis bulunma öyküsü erken başlangıçlı psoriazis olguların-da daha sık saptandı. Sistemik tedaviler arasında en sık retinoik asit, fototerapi türleri arasında en sık dar bant UVB tedavisi kullanıldığı belirlendi. Tartışma: Orta ve şiddetli psoriazis oranı %34 olarak bulundu. Kadın erkek oranı arasında fark saptanmadı. Başlangıç yaşı 16-25 yaş arası pik yapıyordu. En sık eşlik eden sistemik hastalık diyabetes mellitus olarak bulundu. Çalışmamı-zın bulguları literatür ile uyumlu olarak belirlendi. Sonuç olarak psoriazis toplumun yaklaşık %2'sini etkileyen, komorbiditeleri ile hastaların yaşam kalitesini olumsuz yönde etkileyen, kronik, rekürren inflamatuar bir hastalıktır. Özel-likle şiddetli formları, hastalarda ciddi iş gücü kayıplarına neden olabilmektedir. Çalışmamızın psoriazisin demografik ve klinik özelliklerinin daha iyi anlaşılmasına yardım edecek ileri klinik çalışmalara ışık tutacağına inanıyoruz. Anahtar KelimelerPsoriazis; Sosyodemografi; Klinik Özellikler Abstract Aim: In our study, we aim to investigate the demographic, clinic features and the treatments of patients with moderate to severe psoriasis who were followed in outpatient clinic of psoriasis of Department of Dermatology in Istanbul Medical School of Istanbul University. Material and Method: One thousand eight hundred and thirty-one patients, who were followed between 2002-2008 in outpatient clinic of psoriasis, were screened and 626 (34%) of them, who were moderate and severe, were evaluated retrospectively. Results: Three hundred five of the patients who participated in our study were female and 321 were male. Mean age of onset was 28.1. Most frequently clinical type was plaque psoriasis. Most frequently nail involvement was pitting in patients. Nail involvement was statistically common in arthropathic patients. Family history was statistically common in psoriasis patients with early onset. Retinoid was the most common used systemic drug. Narrow band UVB was the most common used phototherapy. Discussion: Moderate to severe psoriasis rate was 34%. Female to male ratio was close to one another. Peak age of onset of psoriasis was between 16-25 years old. The most common concomitant systemic disease was diabetes mellitus. The findings were consistent with the lite...

show abstract

Section: Discussionunclassified

Clinical and Demographic Characteristics of 626 Patients with Moderate and Severe Psoriasis

Rifaioğlu¹,

Özarmağan²

2014

Ann Clin Anal Med

View full text Add to dashboard Cite

show abstract

“…By week 8 of treatment, 82% of patients using pimecrolimus scored their disease as being equally well, or completely controlled, compared with 41% of the vehicle group. The pimecrolimus treatment was also well tolerated (Gribetz et al, 2004).…”

Section: Pimecrolimusmentioning

confidence: 93%

Topical Therapies for Psoriasis

Mitra¹,

Atillasoy²

2012

Psoriasis

View full text Add to dashboard Cite

“…[17][18][19][20][21][22][23][24][25][26][27] Topical Steroids. Topical steroids have been the mainstays of treatment for many years.…”

Section: Topical Therapiesmentioning

confidence: 99%

“…Recently, two industrysponsored RCTs found that tacrolimus improved intertriginous and facial psoriasis compared with placebo (NNT = 3), 24 and that pimecrolimus improved intertriginous psoriasis compared with placebo (NNT = 3). 25 Side effects of tacrolimus and pimecrolimus are mainly burning and itching, and both medications are expensive. Skin cancer and lymphoma have been reported after using these drugs, but causative associations are uncertain.…”

Section: Topical Immunosuppressantsmentioning

confidence: 99%

Chronic Plaque Psoriasis

Luba

Stulberg

2006

South African Family Practice

View full text Add to dashboard Cite

Chronic plaque psoriasis, the most common form of psoriasis, is a papulosquamous disease defined by erythematous plaques with a silvery scale. The diagnosis usually is clinical, but occasionally a biopsy is necessary. Psoriasis affects 0.6 to 4.8 percent of the U.S. population, and about 30 percent of affected patients have a first-degree relative with the disease. Psoriasis is a T-cell-mediated autoimmune disease, but certain medications and infections are well-known risk factors. Management of psoriasis includes education about chronicity, realistic expectations, and use of medication. Steroids and vitamin D derivatives (e.g., calcipotriene) are the mainstays of topical therapy. Topical steroids and calcipotriene together may work better than either agent alone. Patients with psoriasis involving more than 20 percent of their skin or those not responding to topical therapy are candidates for light therapy; traditional systemic therapy; or systemic treatment with immunomodulatory drugs such as alefacept, efalizumab, and etanercept.Reprinted from American Family Physician

show abstract

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study

Cited by 111 publications

References 22 publications

Clinical and Demographic Characteristics of 626 Patients with Moderate and Severe Psoriasis

Clinical and Demographic Characteristics of 626 Patients with Moderate and Severe Psoriasis

Topical Therapies for Psoriasis

Chronic Plaque Psoriasis

Contact Info

Product

Resources

About